AstraZeneca Imfinzi Granted Priority Review and Breakthrough Therapy Designation in US for Patients with Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first...